The current flu vaccine shortage underscores a much greater problem: vaccine development in the U.S. is stagnant, and many producers have exited the market altogether. While some public health officials believe the solution lies in increased government control of development and production, industry officials point to government control—in the form of overly cautious regulation and liability exposure—as the main source of the problem. Panelists at this event will discuss the various factors that impede the U.S. vaccine market from functioning well and will evaluate a number of proposed solutions for the market's problems.
EMAIL
PRINT
SAVE
